Compare Marvell Technology Inc (MRVL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs GeneDx Holdings Corp — how do they compare? Marvell Technology Inc trades at $206.6 (market cap $171.11B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Marvell Technology Inc is far larger — about 95.1× GeneDx Holdings Corp's market cap, and Marvell Technology Inc pays a 0.12% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MRVL | WGS | |
|---|---|---|
Market Cap | $171.11B | $1.80B |
Sector | Technology | Technology |
52-Week High | $316.43 | $167.51 |
52-Week Low | $62.31 | $34.51 |
Enterprise Value | $172.55B | $1.80B |
Dividend Yield | 0.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $207.96, up 10.22% on the day, reflecting strong momentum amid AI-driven chip stock enthusiasm. The stock shows bearish technical signals but benefits from consistent earnings beats and robust analyst support with an 82% buy rating. Recent news highlights its 251% surge in H1 2026 and strategic positioning in AI infrastructure, though volatility persists due to sector-wide capex concerns. Fundamentals reveal high valuation multiples (P/E 66.99) against negative net income, offset by solid gross margins (51.5%) and projected revenue growth to $8.7B in 2026.
Outlook: MRVL offers growth exposure to AI networking and custom silicon, with a consensus price target of $275.68 implying 32% upside. Risks include execution challenges in scaling profitability, debt levels ($3.93B long-term), and sensitivity to AI spending cycles. The stock's premium valuation demands flawless execution to justify current levels amid competitive pressures.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
